{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T03:09:04Z","timestamp":1775617744135,"version":"3.50.1"},"reference-count":31,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Systematically examine the literature describing midodrine to treat shock and to summarize current administration and dosing strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Structured literature search conducted in MEDLINE (PubMed) from inception through May 10, 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction<\/jats:title>\n                    <jats:p>Abstracts and full texts were assessed for inclusion by two blinded, independent reviewers. English-language publications describing use of midodrine in adult patients with shock were included. Data were extracted by two blinded, independent abstractors using a standardized extraction tool. Quality assessments were completed by paired reviewers using JBI methodology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis<\/jats:title>\n                    <jats:p>Fifteen of 698 (2%) screened manuscripts were included with 1,714 patients with a variety of shock types. Seven studies (47%) were retrospective, two (13%) prospective observational, and six (40%) randomized controlled studies. Midodrine was initiated to facilitate intravenous vasopressor (IVP) weaning in most (11, 73%) studies; only two (13%) reported IVP weaning protocol use. Starting doses were 10 mg every 8 hours (4, 27%) or three times a day (3, 20%), 20 mg every 8 hours (2, 13%); six studies (40%) did not report initial midodrine dosing. A midodrine titration protocol was reported in 6 (40%) studies. Thirteen (87%) studies evaluated for bradycardia, identified in 6 (46%) studies among 204 patients; only one (0.5%) patient required midodrine discontinuation. Three (20%) studies reported on hypertension with an incidence of 7\u201311%. Four (27%) studies assessed for ischemia; 5\/1128 (0.4%) patients experienced mesenteric ischemia requiring midodrine discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient care and Clinical Practice<\/jats:title>\n                    <jats:p>This review explores the pragmatic details involved in initiating, titrating, and weaning midodrine for the bedside clinician and identifies rates of adverse events and complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Published literature describing midodrine use for shock is heterogeneous and comprised primarily of low or very low quality data. Future controlled trials addressing the shortcomings identified in this systematic review are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/jccm-2025-0007","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T09:04:29Z","timestamp":1740560669000},"page":"5-22","source":"Crossref","is-referenced-by-count":3,"title":["Midodrine initiation criteria, dose titration, and adverse effects when administered to treat shock: A systematic review and semi-quantitative analysis"],"prefix":"10.2478","volume":"11","author":[{"given":"Madeleine M.","family":"Puissant","sequence":"first","affiliation":[{"name":"Maine Medical Center , Portland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlin J","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Maine Medical Center , Portland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard R","family":"Riker","sequence":"additional","affiliation":[{"name":"Maine Medical Center , Portland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Haydar","sequence":"additional","affiliation":[{"name":"Maine Medical Center , Portland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania D","family":"Strout","sequence":"additional","affiliation":[{"name":"Maine Medical Center , Portland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn E","family":"Smith","sequence":"additional","affiliation":[{"name":"Maine Medical Center , Portland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B","family":"Seder","sequence":"additional","affiliation":[{"name":"Maine Medical Center , Portland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Gagnon","sequence":"additional","affiliation":[{"name":"Maine Medical Center , Portland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"2026022111023810716_j_jccm-2025-0007_ref_001","unstructured":"ProAmatine\u00ae (midodrine hydrochloride) Tablets [package insert]. Lexington, MA: Shire US Inc; 2017."},{"key":"2026022111023810716_j_jccm-2025-0007_ref_002","doi-asserted-by":"crossref","unstructured":"Rizvi MS, Trivedi V, Nasim F, Lin E, Kashyap R, Andrijasevic N, et al. Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case Series. Crit Care Med. 2018;46(7):e628\u201333.","DOI":"10.1097\/CCM.0000000000003121"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_003","doi-asserted-by":"crossref","unstructured":"Rizvi MS, Nei AM, Gajic O, Mara KC, Barreto EF. Continuation of Newly Initiated Midodrine Therapy After Intensive Care and Hospital Discharge: A Single-Center Retrospective Study. Crit Care Med. 2019;47(8):e648\u201353.","DOI":"10.1097\/CCM.0000000000003814"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_004","doi-asserted-by":"crossref","unstructured":"Whitson MR, Mo E, Nabi T, Healy L, Koenig S, Narasimhan M, et al. Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock. Chest. 2016 Jun;149(6):1380\u20133.","DOI":"10.1016\/j.chest.2016.02.657"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_005","doi-asserted-by":"crossref","unstructured":"Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng KN, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998 Jul 1;51(1):120\u20134.","DOI":"10.1212\/WNL.51.1.120"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_006","doi-asserted-by":"crossref","unstructured":"Riker RR, Gagnon DJ. Midodrine administration during critical illness: fixed-dose or titrate to response? Intensive Care Med. 2021 Feb 25;47(2):249\u201351.","DOI":"10.1007\/s00134-020-06321-x"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_007","doi-asserted-by":"crossref","unstructured":"Riker RR, Gagnon DJ. Letter to the Editor: \u201cMidodrine to liberate ICU patients from intravenous vasopressors: Another negative fixed-dose trial\u201d. J Crit Care. 2022 Jun;69:153995.","DOI":"10.1016\/j.jcrc.2022.153995"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_008","doi-asserted-by":"crossref","unstructured":"Al-Abdouh A, Haddadin S, Matta A, Jabri A, Barbarawi M, Abusnina W, et al. Impact of Adjuvant Use of Midodrine to Intravenous Vasopressors: A Systematic Review and Meta-Analysis. Crit Care Res Pract. 2021;2021:5588483.","DOI":"10.1155\/2021\/5588483"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_009","doi-asserted-by":"crossref","unstructured":"Hamed M, Elseidy SA, Elkheshen A, Maher J, Elmoghrabi A, Zaghloul A, et al. The Use of Midodrine as an Adjunctive Therapy to Liberate Patients from Intravenous Vasopressors: A Systematic Review and Meta-analysis of Randomized Controlled Studies. Cardiol Ther. 2023 Mar;12(1):185\u201395.","DOI":"10.1007\/s40119-023-00301-0"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_010","doi-asserted-by":"crossref","unstructured":"Hammond DA, Smith MN, Peksa GD, Trivedi AP, Balk RA, Menich BE. Midodrine as an Adjuvant to Intravenous Vasopressor Agents in Adults With Resolving Shock: Systematic Review and Meta-Analysis. J Intensive Care Med. 2020 Nov;35(11):1209\u201315.","DOI":"10.1177\/0885066619843279"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_011","doi-asserted-by":"crossref","unstructured":"Goradia S, Sardaneh AA, Narayan SW, Penm J, Patanwala AE. Vasopressor dose equivalence: A scoping review and suggested formula. J Crit Care. 2021 Feb;61:233\u201340.","DOI":"10.1016\/j.jcrc.2020.11.002"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_012","doi-asserted-by":"crossref","unstructured":"Barker TH, Stone JC, Sears K, Klugar M, Tufanaru C, Leonardi-Bee J, et al. The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evid Synth. 2023 Mar 1;21(3):494\u2013506.","DOI":"10.11124\/JBIES-22-00430"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_013","doi-asserted-by":"crossref","unstructured":"Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020 Oct;18(10):2127\u201333.","DOI":"10.11124\/JBISRIR-D-19-00099"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_014","unstructured":"Chapter 7: Systematic reviews of etiology and risk. In: JBI Manual for Evidence Synthesis. JBI; 2020."},{"key":"2026022111023810716_j_jccm-2025-0007_ref_015","doi-asserted-by":"crossref","unstructured":"Ahmed Ali AT, Abd El-Aziz MA, Mohamed Abdelhafez A, Ahmed Thabet AM. Effect of Oral Vasopressors Used for Liberation from Intravenous Vasopressors in Intensive Care Unit Patients Recovering from Spinal Shock: A Randomized Controlled Trial. Crit Care Res Pract. 2022;2022:6448504.","DOI":"10.1155\/2022\/6448504"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_016","doi-asserted-by":"crossref","unstructured":"Costa-Pinto R, Yong ZT, Yanase F, Young C, Brown A, Udy A, et al. A pilot, feasibility, randomised controlled trial of midodrine as adjunctive vasopressor for low-dose vasopressor-dependent hypotension in intensive care patients: The MAVERIC study. J Crit Care. 2022;67:166\u201371.","DOI":"10.1016\/j.jcrc.2021.11.004"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_017","doi-asserted-by":"crossref","unstructured":"Wood AJ, Rauniyar R, Jacques A, Palmer RN, Wibrow B, Anstey MH. Oral midodrine does not expedite liberation from protracted vasopressor infusions: A case-control study. Anaesth Intensive Care. 2023 Jan;51(1):20\u20138.","DOI":"10.1177\/0310057X221105297"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_018","doi-asserted-by":"crossref","unstructured":"Adly DH El, Bazan NS, El Borolossy RM, Anan IF, Fakher MA, El Wakeel LM. Midodrine improves clinical and economic outcomes in patients with septic shock: a randomized controlled clinical trial. Ir J Med Sci. 2022 Jan 3;","DOI":"10.1007\/s11845-021-02903-w"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_019","doi-asserted-by":"crossref","unstructured":"Davoudi-Monfared E, Mohammadi M, Khoshavi M, Khalili H. The effect of midodrine on lactate clearance in patients with septic shock: a pilot study. J Comp Eff Res. 2021;10(8):673\u201383.","DOI":"10.2217\/cer-2020-0238"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_020","doi-asserted-by":"crossref","unstructured":"Kim E, Kast C, Afroz-Hossain A, Qiu M, Pappas K, Sinvani L. Bridging the Gap Between the Intensive Care Unit and the Acute Medical Care Unit. Am J Crit Care. 2021;30(3):193\u2013200.","DOI":"10.4037\/ajcc2021591"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_021","doi-asserted-by":"crossref","unstructured":"Lal A, Trivedi V, Rizvi MS, Amsbaugh A, Myers MK, Saleh K, et al. Oral Midodrine Administration During the First 24 Hours of Sepsis to Reduce the Need of Vasoactive Agents: Placebo-Controlled Feasibility Clinical Trial. Crit Care Explor. 2021 May 6;3(5):e0382.","DOI":"10.1097\/CCE.0000000000000382"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_022","doi-asserted-by":"crossref","unstructured":"Macielak SA, Vollmer NJ, Haddad NA, Nabzdyk CGS, Nei SD. Hemodynamic Effects of an Increased Midodrine Dosing Frequency. Crit Care Explor. 2021 Apr 26;3(4):e0405.","DOI":"10.1097\/CCE.0000000000000405"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_023","doi-asserted-by":"crossref","unstructured":"Santer P, Anstey MH, Patroc\u00ednio MD, Wibrow B, Teja B, Shay D, et al. Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial. Intensive Care Med. 2020;46(10):1884\u201393.","DOI":"10.1007\/s00134-020-06216-x"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_024","doi-asserted-by":"crossref","unstructured":"Tremblay JA, Laram\u00e9e P, Lamarche Y, Denault A, Beaubien-Souligny W, Frenette AJ, et al. Potential risks in using midodrine for persistent hypotension after cardiac surgery: a comparative cohort study. Ann Intensive Care. 2020 Sep 14;10(1):121.","DOI":"10.1186\/s13613-020-00737-w"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_025","doi-asserted-by":"crossref","unstructured":"Poveromo LB, Michalets EL, Sutherland SE. Midodrine for the weaning of vasopressor infusions. J Clin Pharm Ther. 2016 Jun;41(3):260\u20135.","DOI":"10.1111\/jcpt.12375"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_026","doi-asserted-by":"crossref","unstructured":"Levine AR, Meyer MJ, Bittner EA, Berg S, Kalman R, Stanislaus AB, et al. Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions. J Crit Care. 2013 Oct;28(5):756\u201362.","DOI":"10.1016\/j.jcrc.2013.05.021"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_027","doi-asserted-by":"crossref","unstructured":"Whitson MR, Mo E, Nabi T, Healy L, Koenig S, Narasimhan M, et al. Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock. Chest. 2016 Jun;149(6):1380\u20133.","DOI":"10.1016\/j.chest.2016.02.657"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_028","doi-asserted-by":"crossref","unstructured":"Sujith Reddy JSN, Jagtap N, Kalpala R, Kulkarni A, Gupta R, Nagaraja Rao P, et al. Midodrine versus Albumin to Prevent Paracentesis Induced Circulatory Dysfunction in Acute on Chronic Liver Failure Patients in the Outpatient Clinic-a Randomized Controlled Trial. J Clin Exp Hepatol. 2023;13(4):576\u201385.","DOI":"10.1016\/j.jceh.2023.01.009"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_029","doi-asserted-by":"crossref","unstructured":"Shrestha DB, Budhathoki P, Sedhai YR, Baniya RK, Karki P, Jha P, et al. Midodrine in Liver Cirrhosis With Ascites: A Systematic Review and Meta-Analysis. Cureus. 2022 Jul;14(7):e27483.","DOI":"10.7759\/cureus.27483"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_030","doi-asserted-by":"crossref","unstructured":"Brunelli SM, Cohen DE, Marlowe G, Van Wyck D. The Impact of Midodrine on Outcomes in Patients with Intradialytic Hypotension. Am J Nephrol. 2018;48(5):381\u20138.","DOI":"10.1159\/000494806"},{"key":"2026022111023810716_j_jccm-2025-0007_ref_031","doi-asserted-by":"crossref","unstructured":"Mongardon N, de Roux Q, Leone M, Guerci P. Norepinephrine formulation for equivalent vasopressive score. Crit Care. 2023 Feb 16;27(1):62.","DOI":"10.1186\/s13054-023-04354-4"}],"container-title":["The Journal of Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciendo.com\/pdf\/10.2478\/jccm-2025-0007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T11:02:48Z","timestamp":1771671768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciendo.com\/article\/10.2478\/jccm-2025-0007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,31]]},"published-print":{"date-parts":[[2025,1,1]]}},"alternative-id":["10.2478\/jccm-2025-0007"],"URL":"https:\/\/doi.org\/10.2478\/jccm-2025-0007","relation":{},"ISSN":["2393-1817"],"issn-type":[{"value":"2393-1817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}